Wearable Devices to Detect CRS Earlier in CAR T-Cell Therapy for Multiple Myeloma
Key Questions
How can wearable devices help in CAR T-cell therapy?
Wearables may detect cytokine release syndrome (CRS) earlier in multiple myeloma patients receiving CAR T therapy. This approach could improve safety and treatment accessibility.
What findings were presented at ASCO 2026 on CAR T therapy?
CU Anschutz researchers, including Manali Kamdar, MD, showcased data building confidence in CAR T therapy for blood cancers. The work highlights innovations like wearables for monitoring.
Why is early CRS detection valuable for myeloma patients?
Detecting CRS sooner allows timely intervention, making CAR T-cell therapy safer. This is particularly relevant for multiple myeloma treatment advancements.
A novel approach using wearable devices to detect cytokine release syndrome (CRS) earlier in patients with multiple myeloma receiving CAR T-cell therapy could make this treatment safer and more accessible. Directly relevant to blood cancer treatment innovation.